De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Eton Pharmaceuticals Beheer
Beheer criteriumcontroles 4/4
De CEO Eton Pharmaceuticals' is Sean Brynjelsen, benoemd in Jun2017, heeft een ambtstermijn van 7.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.75M, bestaande uit 33.9% salaris en 66.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 4.16% van de aandelen van het bedrijf, ter waarde $ 6.45M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 7.1 jaar.
Belangrijke informatie
Sean Brynjelsen
Algemeen directeur
US$1.7m
Totale compensatie
| Percentage CEO-salaris | 33.9% |
| Dienstverband CEO | 7.3yrs |
| Eigendom CEO | 4.2% |
| Management gemiddelde ambtstermijn | 2.5yrs |
| Gemiddelde ambtstermijn bestuur | 7.1yrs |
Recente managementupdates
Recent updates
Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?
Oct 07
After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar
Sep 10Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%
Jan 09The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot
Dec 13Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point
Nov 16Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money
Sep 30Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%
Jul 25Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Jun 29Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?
Dec 22Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous
Sep 13Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story
Aug 14Eton Pharma jumps 20% on FDA approval of seizure therapy
Jul 18Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher
Apr 15Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely
Oct 14Another Look At Eton Pharmaceuticals
Sep 03What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates
Aug 18Eton Pharma wins FDA approval for Rezipres
Jun 15FDA declines to approve Eton Pharmaceuticals' methanol poisoning treatment
May 28Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner
May 15Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Apr 05Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?
Mar 01Eton Pharma buys Canadian rights for Alkindi Sprinkle
Jan 14Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit
Jan 07
Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$7m |
| Mar 31 2024 | n/a | n/a | US$913k |
| Dec 31 2023 | US$2m | US$592k | -US$936k |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | -US$234k |
| Mar 31 2023 | n/a | n/a | -US$6m |
| Dec 31 2022 | US$2m | US$570k | -US$9m |
| Sep 30 2022 | n/a | n/a | -US$9m |
| Jun 30 2022 | n/a | n/a | -US$12m |
| Mar 31 2022 | n/a | n/a | -US$12m |
| Dec 31 2021 | US$2m | US$542k | -US$2m |
| Sep 30 2021 | n/a | n/a | -US$11m |
| Jun 30 2021 | n/a | n/a | -US$11m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$2m | US$476k | -US$28m |
| Sep 30 2020 | n/a | n/a | -US$23m |
| Jun 30 2020 | n/a | n/a | -US$21m |
| Mar 31 2020 | n/a | n/a | -US$20m |
| Dec 31 2019 | US$2m | US$410k | -US$18m |
| Sep 30 2019 | n/a | n/a | -US$42m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$41m |
| Dec 31 2018 | US$493k | US$332k | -US$37m |
| Sep 30 2018 | n/a | n/a | -US$18m |
| Dec 31 2017 | US$654k | US$172k | -US$13m |
Compensatie versus markt: De totale vergoeding ($USD 1.75M ) Sean } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.46M ).
Compensatie versus inkomsten: De vergoeding van Sean is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Sean Brynjelsen (52 yo)
7.3yrs
Tenure
US$1,747,045
Compensatie
Mr. Sean E. Brynjelsen has been the Chief Executive Officer at Eton Pharmaceuticals, Inc. since June 23, 2017 and serves as President and Director since June 2017. Mr. Brynjelsen served as Executive Vice P...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 7.3yrs | US$1.75m | 4.16% $ 8.9m | |
| CFO, Treasurer & Secretary | 2.5yrs | US$785.14k | 0.049% $ 104.0k | |
| Chief Business Officer | 1.6yrs | US$719.08k | 0.081% $ 171.6k | |
| Senior Vice President of Quality & Operations | less than a year | geen gegevens | geen gegevens | |
| Vice President of Sales Operations | no data | geen gegevens | geen gegevens | |
| Executive VP of Commercial Operations | 2.8yrs | geen gegevens | geen gegevens |
2.5yrs
Gemiddelde duur
52yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ETON wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 7.3yrs | US$1.75m | 4.16% $ 8.9m | |
| Independent Director | 7.1yrs | US$129.50k | 0.23% $ 492.9k | |
| Independent Director | 7.3yrs | US$126.90k | 0.26% $ 564.5k | |
| Independent Chairman | 7.1yrs | US$155.50k | 0.23% $ 492.9k | |
| Independent Director | 3.6yrs | US$119.10k | geen gegevens |
7.1yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ETON wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.1 jaar).